Panacea Biotec
India is amongst the top 12 preferred biotech destinations in the world and third largest biotechnology destination in the Asia Pacific region.
Panacea Biotec was established in 1984 under the name Panacea Drugs Private Limited and got publicly listed in September 1995. The company does research and development, manufacturing, sales, distribution and marketing of pharmaceuticals, vaccines and biosimilars. The company’s portfolio includes prescription products in niche therapeutic areas such as pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal care products and vaccines.
- First company to develop fully liquid Pentavalent vaccine (DTwP+Hep B+Hib) Easy Five in 2005.
- It has state-of-art production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi to manufacture tablets, capsules, ointments liquids, herbal formulations and vaccines.
- Consolidated revenue from operations stood at US$ 15.6 million (Rs. 129.14 crore) in the third quarter of FY23.
Panacea Biotec – Innovation in support of life
| Year | Milestone |
|---|---|
| 2023 |
In January 2023, Panacea Biotec donated 125,000 doses of Easy-five TT, which is a fully liquid Pentavalent vaccine to Ministry of Health, Republic of Cuba for use in the National Health System. |
| 2022 |
In October 2022, UNICEF and the Pan American Health Organization (PAHO) awarded Panacea Biotec long-term supply contracts totalling US$ 127.30 million for the provision of its WHO-prequalified fully liquid Pentavalent vaccination, Easyfive-TT® (DTwP-HepB-Hib). In February 2022, Panacea Biotec sold its domestic formulations business to Mankind Pharma for Rs. 1,908 crore (US$ 252.85 million). In February 2022, CEPI, THSTI, and Panacea Biotec partnered to develop broadly protective Betacoronavirus vaccines. |
| 2021 |
In September 2021, Panacea Biotec Limited exported the first shipment of the second dose of the Sputnik V vaccine in India. In May 2021, Panacea Biotec Limited started domestic production of Russia’s Sputnik V vaccine to combat coronavirus |
| 2020 |
Panacea Biotec announced successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll Panacea Biotec and Refana collaborate to develop COVID-19 vaccine Panacea transfers pharmaceuticals business to its wholly owned subsidiary ‘Panacea Biotec Pharma Limited’ |
| 2019 |
Launched ViLACT to treat uncontrolled Type-2 Diabetes Mellitus patients |
| 2018 |
Partnered with Serum Institute of India to expand market access for the world's first fully liquid
wP-based hexavalent vaccine, EasySix. It vaccinates children against DTwP, Hib, Hep. B and
Polio |
| 2017 |
Panacea Biotec announced acceptance of its abbreviated new drug application (ANDA) for paclitaxel
protein bound particles by the US FDA |
| 2014 |
Partnered with a leading pharmaceutical company (name undisclosed) to develop and supply an immunosuppressant generic product in the US |
| 2013 |
Received WHO PQ for EasyFive TT |
| 2012 |
Partnered with Kremers Urban for 11 High Barrier to Entry Generics and launched Tacrolimus Capsules in the US |
| 2007 |
Partnered with Punjab University to develop new chemical entities |
| 2006 |
Panacea Biotec partnered with Nederlands Vaccine Instituut under which the latter would supply bulk
Inactivated Polio Vaccines (IPV), which will be used by the company in the manufacture of finished
IPV and several IPV based combination vaccines |
| 2004 |
Collaborated with Cambridge Bio-stability, the UK, for thermo stable vaccines |
| 2002 |
Recombinant vaccine production plant was commissioned |
| 2001 |
Collaborated with a European MNC for R&D |
| 1995 |
Established State -of the- art drug delivery R&D centre at Lalru |
| 1993 |
Panacea Biotec Ltd. was formed with the merger of Panacea Drugs (P) Ltd. & Radicura Pharma |
| 1988 |
Established a plant to produce vaccines at New Delhi, under the name of Radicura Pharma |
Partners
